Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles.

We applied cDNA microarray analyses of 9216 genes to establish a genetic method for predicting the outcome of adjuvant chemotherapy to esophageal cancers. We analyzed expression profiles of 20 esophageal cancer tissues from patients who were treated with the same adjuvant chemotherapy after removal of tumor by operation, and we attempted to find genes associated with the duration of survival after surgery. By comparing expression profiles of those cancer tissues, we identified by statistical analysis 52 genes that were likely to be correlated with prognosis and possibly with sensitivity/resistance to the anticancer drugs. We also developed a drug response score based on the differential expression of these genes, and we found a significant correlation between the drug response score and individual patients' prognoses. Our results indicated that this scoring system, based on microarray analysis of selected genes, is likely to have great potential for predicting the prognosis of individual cancer patients with the adjuvant chemotherapy.

[1]  B. Mirkin,et al.  S-adenosylmethionine synthetase is overexpressed in murine neuroblastoma cells resistant to nucleoside analogue inhibitors of S-adenosylhomocysteine hydrolase: a novel mechanism of drug resistance. , 1999, Cancer research.

[2]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[3]  M. Hollstein,et al.  Amplification of Epidermal Growth Factor Receptor Gene but Updated Version Citing Articles E-mail Alerts Amplification of Epidermal Growth Factor Receptor Gene but No Evidence of Ras Mutations in Primary Human Esophageal Cancers , 2013 .

[4]  T Tanaka,et al.  Identification by cDNA microarray of genes involved in ovarian carcinogenesis. , 2000, Cancer research.

[5]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[6]  J. Eberwine,et al.  Amplified RNA synthesized from limited quantities of heterogeneous cDNA. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Eddy,et al.  Two chromosomal locations for human ornithine decarboxylase gene sequences and elevated expression in colorectal neoplasia. , 1990, Cancer research.

[8]  Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. , 1997, Oncology.

[9]  T. Takagi,et al.  Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. , 2001, Cancer research.

[10]  J. Forbes,et al.  EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival , 1998, Oncogene.

[11]  M. Bittner,et al.  Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. , 1998, Cancer research.

[12]  T. Sugiyama,et al.  Gene amplification of int-2 and erbB in human esophageal cancer: relationship to clinicopathological variables. , 1997, Cancer investigation.

[13]  W. Hop,et al.  Reduced expression of the cadherin–catenin complex in oesophageal adenocarcinoma correlates with poor prognosis , 1997, The Journal of pathology.

[14]  D. Beer,et al.  Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomas , 1993, International journal of cancer.

[15]  M. Jackson,et al.  Gene expression profiles of laser-captured adjacent neuronal subtypes , 1999, Nature Medicine.

[16]  J. Nesland,et al.  P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. , 2000, Anticancer research.

[17]  T. Zhukov,et al.  Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  J. Hainsworth,et al.  Phase I/II trial of paclitaxel by 1‐hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma , 1999, Cancer.

[19]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[20]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  V. Chiarion-Sileni,et al.  First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up. , 1997, Annals of surgery.

[22]  J. Morizet,et al.  Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues. , 1993, Cancer research.

[23]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[24]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[25]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[26]  M. Bittner,et al.  Data management and analysis for gene expression arrays , 1998, Nature Genetics.